Metraipolis › archive › dc_ca08c6db529f
Training rhesus macaques to take daily oral antiretroviral therapy for preclinical evaluation of HIV prevention and treatment strategies — Europe PMC PMID:31730629
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/31730629
- DOI
- 10.1371/journal.pone.0225146
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-10T02:20:29.054Z
- SHA-256 of the archived text
34f648540bebf76ccb79fb7194f13ac66cd6146344126e2724031122c0afba12- Stable URL of this page
https://metraipolis.com/documento/dc_ca08c6db529f
How to cite
Training rhesus macaques to take daily oral antiretroviral therapy for preclinical evaluation of HIV prevention and treatment strategies — Europe PMC PMID:31730629 — Europe PMC (en), https://europepmc.org/article/MED/31730629 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_ca08c6db529f (Metraipolis archive dc_ca08c6db529f, sha256 34f648540bebf76ccb79fb7194f13ac66cd6146344126e2724031122c0afba12)
BibTeX
@misc{dcca08c6db529f,
title = {Training rhesus macaques to take daily oral antiretroviral therapy for preclinical evaluation of HIV prevention and treatment strategies — Europe PMC PMID:31730629},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/31730629},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_ca08c6db529f; sha256 34f648540bebf76ccb79fb7194f13ac66cd6146344126e2724031122c0afba12},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/31730629. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Macaque models of simian or simian/human immunodeficiency virus (SIV or SHIV) infection are critical for the evaluation of antiretroviral (ARV)-based HIV treatment and prevention strategies. However, modelling human oral ARV administration is logistically challenging and fraught by limited adherence. Here, we developed a protocol for administering daily oral doses of ARVs to macaques with a high rate of compliance. Methods: Parameters of positive reinforcement training (PRT), behavioral responses and optimal drug delivery foods were defined in 7 male rhesus macaques (Macaca mulatta). Animals were trained to sit in a specified cage location prior to receiving ARVs, emtricitabine (FTC) and tenofovir alafenamide (TAF), in a blended food mixture, which was followed immediately with a juice chaser. Consistency of daily oral adherence was evaluated in 4 trained macaques receiving clinically equivalent doses of FTC and TAF (20 and 1.5 mg/kg, respectively) in a short-term (1 month) and an extended (6 month) trial. Adherence was monitored using medication diaries and by quantifying intracellular FTC-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) concentrations in peripheral mononuclear blood cells (PBMCs). Results: Trained macaques quickly and consistently took daily oral ARVs for 1 month with an average 99.8% observed adherence. Intracellular concentrations of TFV-DP (median = 845.8 fmol/million cells [range, 620.8-1031.3]) and FTC-TP (median = 367.0 fmol/million cells [range, 289.5-413.5) in PBMCs were consistent with high adherence. Extended treatment with select subjects yielded similar observations for three months (99.5% adherence, 352/356 complete doses taken), although a sudden drop in adherence was observed after splenic biopsy surgery. Conclusions: We demonstrate that trained macaques reliably adhere to a daily oral ARV regimen, although unexpected adherence issues are possible. Our approach, using clinical doses of oral FTC and TAF daily, further refines macaque models of HIV treatment and prevention by mimicking the human route and timing of ARV administration. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2019 (prima pubblicazione 2019-11-15). Identificativi: PMID 31730629 · PMCID PMC6857902 · DOI 10.1371/journal.pone.0225146. Pagina: https://europepmc.org/article/MED/31730629 — https://doi.org/10.1371/journal.pone.0225146. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-10T02:17:33.599Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.